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ABSTRACT
Humanmonocytic and professional antigen-presenting cells have been reported only to exhibit abortive infections with vaccinia
virus (VACV).We found that monocyte-derived macrophages (MDMs), including granulocyte macrophage colony-stimulating
factor (GM-CSF)-polarizedM1 andmacrophage colony-stimulating factor (M-CSF)-polarizedM2, but not human AB serum-
derived cells, were permissive to VACV replication. The titers of infectious virions in both cell-free supernatants and cellular
lysates of infectedM1 andM2markedly increased in a time-dependent manner. The majority of virions produced in permissive
MDMs were extracellular enveloped virions (EEV), a secreted form of VACV associated with long-range virus dissemination,
and were mainly found in the culture supernatant. InfectedMDMs formed VACV factories, actin tails, virion-associated branch-
ing structures, and cell linkages, indicating that MDMs are able to initiate de novo synthesis of viral DNA and promote virus re-
lease. VACV replication was sensitive to inhibitors against the Akt and Erk1/2 pathways that can be activated by VACV infection
andM-CSF stimulation. Classical activation of MDMs by lipopolysaccharide (LPS) plus gamma interferon (IFN-) stimulation
caused no effect on VACV replication, while alternative activation of MDMs by interleukin-10 (IL-10) or LPS-plus-IL-1 treat-
ment significantly decreased VACV production. The IL-10-mediated suppression of VACV replication was largely due to Stat3
activation, as a Stat3 inhibitor restored virus production to levels observed without IL-10 stimulation. In conclusion, our data
demonstrate that primary humanmacrophages are permissive to VACV replication. After infection, these cells produce EEV for
long-range dissemination and also form structures associated with virions which may contribute to cell-cell spread.
IMPORTANCE
Our results provide critical information to the burgeoning fields of cancer-killing (oncolytic) virus therapy with vaccinia virus
(VACV). One type of macrophage (M2) is considered a common presence in tumors and is associated with poor prognosis. Our
results demonstrate a preference for VACV replication inM2macrophages and could assist in designing treatments and engi-
neering poxviruses with special considerations for their effect onM2macrophage-containing tumors. Additionally, this work
highlights the importance of macrophages in the field of vaccine development using poxviruses as vectors. The understanding of
the dynamics of poxvirus-infected foci is central in understanding the effectiveness of the immune response to poxvirus-medi-
ated vaccine vectors. Monocytic cells have been found to be an important part of VACV skin lesions in mice in controlling the
infection as well as mediating virus transport out of infected foci.
Orthopoxvirus, a genus of the subfamily Chordopoxvirinae ofthe family Poxviridae, is composed of large DNA viruses that
infect a wide array ofmammalian species. Themost famousmem-
ber of the genus is the human-specific variola virus, which causes
smallpox. In nature, variola virus has a strict human-specific tro-
pism, and nonhuman reservoirs of the virus have never been
found. Variola virus is generally transmitted via inhalation, with
subsequent infection and replication in epithelial cells of the oral
and respiratory mucosa. The next stage of infection involves viral
infiltration of lymphoid organs accompanied by strong viremia
and skin lesions. Recent studies using high doses of variola virus to
infect Cynomolgus macaques in an attempt to develop an animal
model of smallpox have demonstrated that infected animals de-
velop systemic infection and hemorrhagic symptoms (1, 2). These
symptomswere correlated withmonocyte/macrophage-mediated
viremia and dissemination (1, 2). In mice, macrophages are cru-
cial to control the infection of the orthopoxvirus ectromelia virus
(ECTV) (3, 4). However, ECTV replicates inmacrophages (5) and
directly contributes to dissemination within the host (6). Given
their importance in defense against invading pathogens, macro-
phages likely act as a double-edged sword in certain orthopoxvirus
infections, mediating both infection control and virus dissemina-
tion.
The relatively benign vaccinia virus (VACV), the prototypical
member of the orthopoxvirus genus, has a genome 95% homolo-
gous to variola virus (7) and is most often used as a model of
orthopoxvirus infection. With its high antigenic homology, VACV
has been crucial as a live vaccine for the global eradication of
smallpox throughout the 20th century. VACV produces four vi-
rion forms, including the single-enveloped intracellular mature
virion (IMV), triple-enveloped intracellular enveloped virion
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(IEV), the double enveloped, cell-associated enveloped virion
(CEV), and extracellular enveloped virion (EEV) (8). Similar to
variola virus but without the severe effects, VACV can produce a
generalized infection which involves EEV viremia with subse-
quent infection of distant sites on the skin (8). Additionally, CEV
can rapidly transfer between neighboring cells in culture via actin
tails (9), although the precise routes of long-range dissemination
via viremia are unknown. Visualizations of VACV skin lesions in
mice have shown that highly motile infected macrophages are
adjacent to infected skin foci (10). Extraction and analysis of these
macrophages have revealed that the cells are permissively infected
and are associated with 7% of the total VACV in the lesion (10).
Thus, macrophages have been exhibited in mammals as potential
candidates for mediating long-range VACV dissemination. One
report has demonstrated that the infection of primary human
macrophages is abortive (11). This study demonstrated that cells
only support early stages of the VACV infection cycle, including
morphological cytopathic effects, deactivation of host protein
synthesis, and activation of early viral protein synthesis, but not
late infection stages, including synthesis of late viral proteins, rep-
lication of viral DNA, and production of infectious progeny viri-
ons (11). VACV infection of primary humanmonocytes and den-
dritic cells (DCs) has also been demonstrated to be abortive in vivo
and in vitro (12–18), where viralDNA is onlyweakly replicated, no
late genes are transcribed, and no actin tails or viral factories form.
Hence, it has been speculated that, in humans, VACV cannot rep-
licate in monocytic cells, includingmonocytes, macrophages, and
DCs.
Macrophages are found in tissues throughout the body inmost
organs. These tissue macrophages are mainly derived from circu-
lating monocytes but are difficult to collect and study. To obtain
macrophages, researchers have developed several approaches to
differentiate primary blood monocytes by incubating them with
(i) media containing human AB serum or fetal bovine serum
(FBS) (19), (ii) media containing FBS supplemented with granu-
locyte-macrophage colony-stimulating factor (GM-CSF) or M-
CSF (20, 21), or (iii) conditional serum-free media with or with-
out GM-CSF or M-CSF (22, 23). These different methods of
MDM generation have not been systematically related to each
other functionally or transcriptionally. GM-CSF-induced MDMs
replicate some of the functions and transcriptional profiles of clas-
sically activated proinflammatory (M1) cells in vivo, while
M-CSF-induced MDMs tend to replicate alternatively activated
anti-inflammatory (M2)macrophages (24). Gene expression pro-
filing studies of murine M2 cells have found some common ex-
pression of genes betweenM2 cells generated in vitro andM2 cells
from in vivo disease models (25, 26). In vitro M1 and M2 macro-
phages largely mirror the functional phenotypes of macrophages
in vivo for allergy, parasitic infections, and certain cancers (27),
but other pathological conditions, such as neurodegenerative dis-
eases, express unique macrophage phenotypes. In contrast, hu-
manAB serum-derivedMDMs have not been related to particular
states in vivo so far. In the study reported here, we found that both
M1- and M2-polarized macrophages were permissive for VACV
infection and replication, whereas human AB serum-derived
MDMs could be infected butwere abortive, as reported previously
(11). Infected M1 and M2 MDMs mainly produced EEV and ex-
hibited virion-associated structures that may promote virus
spread to neighboring cells. VACV replication was found to be
dependent on known poxvirus-associated signaling pathways,
and the activation of Stat3 was strongly inhibitory to virus pro-
duction.
MATERIALS AND METHODS
Ethics statement. Whole-blood samples or leukapheresis products were
obtained from healthy blood donors with written consent obtained from
each participant. Investigational protocols were approved by Institutional
Review Boards for Human Research at the Indiana University School of
Medicine (Indianapolis, IN).
Preparationof primaryhumanmonocyte-derivedmacrophages.To
isolate peripheral bloodmononuclear cells (PBMCs), whole blood or leu-
kapheresis products obtained from healthy blood donors were separated
by Ficoll-Hypaque (AmershamPharmacia Biotech AB, Uppsala, Sweden)
gradients. PBMCs were subjected to monocyte isolation using the mono-
cyte negative isolation kit (Dynal, Oslo, Norway). Monocyte purity was
determined to be95% by CD14 staining and fluorescence-activated cell
sorting (FACS). To differentiate cells into macrophages, isolated mono-
cytes were cultured in complete RPMI 1640 medium (RPMI 1640 me-
dium supplemented with 10% fetal bovine serum [FBS], 2 mM L-glu-
tamine, 100 U/ml penicillin, and 100 U/ml streptomycin) supplemented
with either 50 ng/ml of recombinant human GM-CSF (rhGM-CSF), 50
ng/ml of rhM-CSF, or RPMI 1640 containing 10% human AB serum
(Gemini Bio Products, West Sacramento, CA). Culture media were
changed every 3 days. Macrophages were considered fully differentiated
by 7 days of culture as determined by morphology. Resting T cells were
isolated from the PBMCs using a Pan T cell isolation kit II (Miltenyi
Biotec, Auburn, CA), which yielded95% purity of CD3 T cells. CD3
T cells were activated by incubating with anti-CD3/anti-CD28 antibody
(Ab)-coated magnetic beads (Life Technologies, Carlsbad, CA) and al-
lowed to culture in complete RPMI 1640 medium for 72 h before use in
experiments.
Cytokines, antibodies, and flow-cytometric analysis. The following
recombinant human xeno-free cytokines for cell culture were purchased
from EMDMillipore (Darmstadt, Germany): recombinant human inter-
leukin-1 (rhIL-1), rhIL-10, and recombinant human gamma inter-
feron (rhIFN-). rhM-CSF and rhGM-CSF (carrier-free) were purchased
from BioLegend (San Diego, CA). Ultrapure lipopolysaccharide (LPS)
derived from Salmonella enterica serotypeMinnesota R595was purchased
from InvivoGen (San Diego, CA). The following mouse anti-human
monoclonal antibodies (MAbs) conjugated with fluorochromes were
purchased from BioLegend (San Diego, CA): anti-CD68 conjugated with
Alexa Fluor 488, anti-CD163 conjugated with phycoerythrin (PE), and
anti-CD86 conjugated with allophycocyanin. For intracellular staining
(ICS) of Stat3 activation or caspase-3, cells were fixed with 2% parafor-
maldehyde (PFA), permeabilized with 0.1% saponin, and stained with
mouse anti-human Stat3 phospho-Tyr705 conjugated with Alexa Fluor
647 or rabbit anti-human caspase-3 (active form) conjugated with fluo-
rescein isothiocyanate (FITC) (BD Biosciences, San Jose, CA). Staining
for apoptosis and necrosis with annexin V-FITC plus propidium iodide
(PI) was performed using the annexin-V-FLUOS staining kit (Roche,
Mannheim, Germany) according to the manufacturer’s instructions.
FACS was performed using a BD FACSCalibur (BD Biosciences, San Di-
ego, CA), and data were analyzed using FlowJo software (TreeStar, San
Carlos, CA). For control staining, appropriate fluorochrome-conjugated
isotype-matched controls purchased from BD Biosciences (San Jose, CA)
were used in tandem with test Abs.
VACV purification, titration, and infection protocols. The primary
VACV strain used in this study wasWestern Reserve (WR). The enhanced
green fluorescent protein (EGFP) reporter virus, VV-EGFP, is aWR strain
containing a chimeric gene and includes the influenza virus nucleopro-
tein, the ovalbumin SIINFEKL peptide, and EGFP that localizes to the
nucleus (28). Both VACV WR and VV-EGFP were obtained from J. W.
Yewdell (NIH, Bethesda, MD). vA5L-YFP is a recombinant WR VACV
constructed with the viral core protein A5L fused to yellow fluorescence
protein (YFP), which is suitable for visualizing individual virions (29).
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This virus was obtained from B. Moss (NIH, Bethesda, MD). Viral stocks
were generated and titrated in chicken embryo fibroblasts (Charles River
Laboratories, Wilmington, MA) or the monkey kidney cell line CV-1
(ATCC, Manassas, VA) in complete RPMI 1640 medium. After 3 days of
infection, cells were lysed in aDounce homogenizer. Culture supernatants
and cell lysateswere then subjected to ultracentrifugation at 25,000 g for
80 min through a 36% sucrose cushion. Pellets were resuspended and
subjected to virus purification by ultracentrifugation through a 24 to 40%
sucrose gradient as previously described (30). Viral titers were determined
by a virus plaque assay. Briefly, CV-1 cells were grown in 6-well plates to
90% confluence and overlaid with various dilutions of purified virus.
After 1 h of incubation, cells were washed and overlaid with complete
RPMI 1640 containing 1.5% carboxylmethylcellulose to prevent de novo
EEV plaque formation. After 2 to 3 days of culture, cells were stained with
a 0.01% crystal violet and 15% ethanol solution and then washed so that
plaques could be counted to calculate virus PFU.
For all experiments involvingVACV infection of primaryMDMs, cells
were first plated in 12- or 6-well plates with 50,000 to 300,000 cells per
well, incubated with VACV WR at a multiplicity of infection (MOI) of 5
for 1 h, washed three times with phosphate-buffered saline (PBS), and
allowed to culture for 2 days in complete RPMI 1640. Culture supernatant
and cells were harvested at various time points. Cells and supernatants
were frozen and thawed three times, followed by sonication in a cup horn
sonicator. Cell lysates and supernatants were either mixed together or
analyzed separately for virus titers using the virus plaque assay. VV-EGFP
was used to monitor viral gene expression in MDMs, except cells were
cultured for a short period (6 h) to allow EGFP expression only. At 6 h of
culture, cells were fixed with 2%PFA, and EGFP-positive cells were quan-
titated using FACS. For VACV binding assays, primary MDMs were
chilled to 4°C and incubated with vA5L-YFP at an MOI of 5 on ice for 30
min with gentle mixing (VACV binding condition). Cells were washed
three times with ice-cold PBS and fixed with 2% PFA, and YFP-positive
cells were quantitated using FACS.
Macrophage activation and RT-PCR transcriptional profiling.
MDMs were activated using different cytokine combinations. First, iso-
lated blood monocytes were cultured in complete RPMI 1640 supple-
mentedwith either 50 ng/ml of rhGM-CSF or 50 ng/ml of rhM-CSF. After
7 days of differentiation, GM-CSF-inducedMDMs (M1) were stimulated
with 10 ng/ml of LPS plus 50 ng/ml of rhIFN-. M-CSF-induced MDMs
(M2) were activated with either 10 ng/ml of rhIL-4 (M2a), 10 ng/ml of
LPS plus 10 ng/ml of rhIL-1 (M2b), or 10 ng/ml of rhIL-10 (M2c). Cells
were cultured for 24 h. For inhibition of Jak2/Stat3 duringM2c activation,
1 to 5 M cucurbitacin I (JSI-124; Sigma-Aldrich, St. Louis, MO) was
added alongwith rhIL-10. For reverse transcription-PCR (RT-PCR) anal-
ysis of activation-associated genes, cells were washed three times with PBS
and subjected to RNA extraction using an RNeasy minikit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions. RNA
was subjected to cDNA synthesis using the Superscript III first-strand
synthesis kit (Life Technologies, Carlsbad, CA) according to the manu-
facturer’s instructions. Real-time RT-PCR was performed using the RT2
SYBR green/ROX FAST master mixes (Qiagen, Hilden, Germany) with
primers against M1- or M2-specific genes, including the following: IL-6
forward, 5=-GAGGATACCATCCCAACAGACC-3=; IL-6 reverse, 5=-AA
GTGCATCATCGTTGTTCATACA-3=; IL-10 forward, 5=-GCCTAACAT
GCTTCGAGA-3=; IL-10 reverse, 5=-TGATGTCTGGGTCTTGGTTC-3=;
CD163 forward, 5=-CCAGTCCCAAACACTGTC-3=; CD163 reverse, 5=-
TTCTGGAATGGTAGGCCTTG-3=; Arg1 forward, 5=-CAGAAGAATGG
AAGAGTCAG-3=; Arg1 reverse, 5=-CAGATATGCAGGGAGTCACC-3=;
-actin forward, 5=-CTCGACACCAGGGCGTTAG-3; and -actin re-
verse, 5=-CCACTCCATGCTCGATAGAT-3= (Life Technologies, Carls-
bad, CA). Expression data by the cycle threshold (CT) valuewas compared
to actin expression and analyzed using the 2		CT method as previously
described (31). For infection of activated cells, M1- or M2-polarized cells
were infected with VACV WR at an MOI of 5 for 3 h. Cells were washed
extensively with PBS and then cultured in medium containing activation
cytokines.
CsCl density gradient ultracentrifugation for VACV separation.Vi-
rus-containing supernatant and cell pellet were harvested from 5  107
VACV-infectedM2macrophages. To separate and analyze mature versus
enveloped virus particles, virus was purified from cell lysates via 24 to 40%
sucrose gradients. Purified virus was added to CsCl gradients made with 2
ml of 1.30 g/ml overlaid with 3 ml of 1.25 g/ml, followed by 4 ml of 1.20
g/ml in a 12-ml tube, as previously described (32, 33), and spun in an
Optima LE-80K ultracentrifuge with an SW-41 rotor (Beckman Coulter,
Brea, CA) for 2 h at 120,000 g (32,000 rpm) at 20°C. Fractions (0.5ml of
each) were harvested from the top of each gradient and subjected to virus
collection by ultracentrifugation at 21,000 g (15,000 rpm) for 30min in
a tabletop microcentrifuge. Virus pellets were resuspended in 100 l of
PBS and sonicated with a cup horn sonicator. The absorbance of each
fraction was measured at 260 nm, and the number of virion particles was
estimated using the following calculation: numbers of virus particles 

A260 (1.2 10
10).
Signaling pathway inhibition in human primarymacrophages.M2-
polarized MDMs were infected with VACV WR at an MOI of 5 for 3 h.
Cells were washed three times with PBS and incubated in complete RPMI
with 5 to 40 M Akt inhibitor LY294002 or 1 to 100 M Erk inhibitor
PD98059. After incubation for 24 to 48 h, cells or supernatants were sub-
jected to virus extraction to determine virus titers using the virus plaque
assay. Cell lysates were also subjected to enzyme-linked immunosorbent
assays (ELISAs) to determine the degree of signaling reduction by inhib-
itors using the Pathscan phospho-Akt1 and Pathscan phospho-p44 mito-
gen-activated protein kinase (MAPK) sandwich ELISA kits (Cell Signaling
Technology, Danvers, MA) according to the manufacturer’s instructions.
With the same kits, Abs against Akt and Erk (Cell Signaling Technology)
were used to detect levels of total Akt and Erk, respectively.
Confocalmicroscopy.MDMswere infected with vA5L-YFPVACV at
an MOI of 5 and fixed at various intervals. To stain extracellular virions,
cells were stainedwith rabbit polyclonal antiserumNR-565 against VACV
WR A33 (NIH Biodefense and Emerging Infections Research Resources
Repository, NIAID, NIH), followed by secondary Ab of goat anti-mouse
IgG HL conjugated to Alexa Fluor 546 (Life Technologies, Carlsbad,
CA). In a separate condition, infected cells were fixed with 2% PFA, per-
meabilized with 0.1% saponin, and incubated with phalloidin conjugated
with Alexa Fluor 546 (Life Technologies, Carlsbad, CA) for F-actin stain-
ing. Cells were then mounted onto glass slides using ProLong Gold anti-
fade reagent (Life Technologies, Carlsbad, CA) containing 4=,6-di-
amidino-2-phenylindole (DAPI) dye for DNA staining. Slides were
viewed using an Olympus FV1000-MPE confocal/multiphoton micro-
scope fitted with a 60 water objective. Images were processed using
ImageJ software (version 1.47; NIH, Bethesda, MD).
Statistical analysis. Data obtained from two groups were analyzed
using the Student’s t test, while data obtained from three groups or more
were analyzed using Tukey’s post hoc analysis of variance (ANOVA) test.
Values of P 0.05 were considered statistically significant.
RESULTS
VACV replicated in M1- and M2-polarized, but not human AB
serum-derived, macrophages. It has been previously reported
that VACV exhibits an abortive infection in primary human
MDMs derived from peripheral blood monocytes by culturing
them in medium containing 10% human AB serum (11). We in-
fected human AB serum-derived MDMs with VACV WR at an
MOI of 5 for 3 h to 48 h and found that VACV did not replicate, as
virus plaque numbers did not increase (Fig. 1A), corroborating
the previous report (11). Compared to MDM generated with hu-
manAB serum, it is known that supplementation ofmediumwith
GM-CSF or M-CSF was found to generate M1- or M2-polarized
cells, respectively, and promote cell survival (34). After deriving
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MDMs with these cytokines, both M1- and M2-polarized MDMs
expressed the low-density lipoprotein (LDL)-binding glycopro-
tein CD68, a common macrophage marker, while only M-CSF-
polarized cells markedly expressed the scavenger receptor CD163,
a surface marker for M2 MDMs (Fig. 1B). In contrast to MDMs
derived from human AB serum, GM-CSF- and M-CSF-derived
MDMs were permissive to VACV infection and replication (Fig.
1C). At anMOI of 5, GM-CSF-polarized cells produced 11.3 2.1
virions per cell at 24 h and 15.3  1.2 virions per cell at 48 h.
M-CSF-polarized cells produced 24.5 2.3 virions per cell at 24 h
and 31.7 3.1 virions per cell at 48 h. In comparison, HeLa cells,
a human epithelial carcinoma cell line widely used for VACV in-
fection and replication, produced 44.0 6.0 virions per cell at 24
h and 56.7 5.5 virions per cell at 48 h. Primary T cells activated
with anti-CD3 and anti-CD28 Abs were also productive, as previ-
ously reported (35), but only produced 1.8 0.8 virions per cell at
24 h and 3.3 1.5 virions per cell at 48 h (Fig. 1C). Thus, VACV
replicates in primary human M1 and M2 cells and relatively less
efficiently in activated T cells, but it does not replicate in human
AB serum-derivedMDMs. After 24 h of infection with vA5L-YFP,
expression of the late viral protein A5L was almost exclusively
found on CD68 cells for both M1- and M2-polarized MDMs
(Fig. 1D). Under the same conditions, CD163 surface expression
was highly correlative to A5L expression in M2-polarized MDMs
(Fig. 1E).
To understand whether the different degrees of VACV replica-
tion in the three types of MDMs (M1-, M2-, and human AB se-
rum-derivedMDMs) are directly related to efficacy of virus bind-
ing to and infection of these cell types,MDMswere incubatedwith
vA5L-YFP under binding conditions (on ice for 30 min) or in-
fected with VV-EGFP, a VACV WR strain containing an EGFP
reporter gene regulated under a VACV early/late promoter, for a
short period (6 h; early infection). YFP-positive or EGFP-posi-
tive cells were quantitated by FACS. No significant differences in
either virus binding or early infection were observed among these
three MDM types (Fig. 1F), suggesting that VACV binding and
early infection is comparable among human GM-CSF-, M-CSF-,
and AB serum-derived cells. VACV infection was previously re-
ported to induce apoptosis in murine macrophage cell line
J774.G8 (36). To investigate the fates of VACV infection in pri-
mary human cells, apoptosis wasmonitored by intracellular stain-
ing of active caspase-3. No significant levels of caspase-3-positive
MDMswere detected, and the levels did not increase within 2 days
of VACV infection (Fig. 1G). This result was in contrast to those
for uninfected primary human monocytes that underwent spon-
taneous apoptosis in in vitro culture (37) (Fig. 1G). Additionally,
infectedMDMswere stainedwith propidium iodide (PI) to detect
necrotic cells, and no increase in PI-positive cells was observed
(Fig. 1G). This result was concordant with observations that cell
numbers were never significantly decreased throughout the 2-day
infection and no nucleosomal units or apoptotic bodies were ob-
served throughout extensive viewing by confocal microscopy
(data not shown). It is notable that detection of surface phospha-
tidylserine with annexin V was not an appropriate assay for this
experiment, as VACVwas found to express phosphatidylserine on
the virion surface (38, 39). We found that most cells were positive
for annexin V staining after virus binding and throughout the
infection (data not shown). Therefore, MDMs derived from hu-
man AB serum, GM-CSF, or M-CSF treatment have a similar
degree of viral binding and early infection and do not undergo
apoptosis within 2 days of infection.
Virus factories, actin tails, and branching structures formed
in VACV-infected macrophages. Virus factories (also known as
virosomes) and actin tails are well documented in VACV-infected
cell lines and could not be detected in infected primary DCs, as
these DCs are not permissive for VACV replication (17). To fur-
ther investigate the cellular effects of VACV infection and replica-
tion in MDMs, we searched for the presence of these common
structures associated with VACV-infected cell lines. At various
stages of vA5L-YFP infection,monocytes orM2-polarizedMDMs
were visualized using confocal microscopy. In addition, F-actin
was stained with phalloidin conjugated to the fluorophore Alexa
Fluor 647 to observe actin dynamics throughout the infection. In
agreement with the results obtained from the virus plaque assay,
primary monocytes showed no visible increase in VACV particles
after 24 h of infection (Fig. 2A). In contrast, VACV replication in
MDMs was apparent, as numbers of cell-associated virions were
increased (Fig. 2B). Characteristically, VACV infection in cell lines
such as HeLa cells leads to the formation of perinuclear virus
factories that coopt a section of the endoplasmic reticulum (ER)
for VACV DNA replication and initial virus assembly (40). After
24 h of infection, perinuclear VACV factory structures with high
levels of A5L expression were observed in M2-polarized MDMs
(Fig. 2C) but not in monocytes (Fig. 2A). These perinuclear fac-
tory structures in M2 MDMs exhibited DAPI staining, indicating
VACV DNA replication (Fig. 2C).
CEV virions in cell lines protrude from the cell surface via actin
polymerization (41). This process requires certain host factors,
such as Abl tyrosine kinases (42) and the products of VACV genes
A36, A33, A34, and B5R (8). We found that VACV virions associ-
ated with actin tails in MDMs became visible by 3 h postinfection
and persisted throughout the course of infection (Fig. 2D). Addi-
tionally, VACV virions were frequently observed to congregate
inside projections linking neighboring cells together and in areas
with lamellipodia-associated protrusions (Fig. 2B, white arrows,
and E). Virus-induced branching between cells also occurred (Fig.
2B and F), which is reminiscent of the elongation and branching
observed in infected cell lines, such as BS-C-1 (43). The VACV-
associated lamellipodia and branching may represent a strategy
for cell-to-cell transmission which can be visualized by live imag-
ing assays. VACV-associated branching structures, actin tails, and
virus factories were also observed in infected M1-polarized
FIG 1 VACV replicated in M1- and M2-polarized macrophages. MDMs derived from treatment of human AB serum (A), GM-CSF (C), or M-CSF (C) were
infected with VACVWR at anMOI of 5, and virions were harvested from cell lysates at 3, 24, and 48 h of postinfection for the virus plaque assay. (B)MDMswere
subjected to surface staining and FACS tomeasure humanmacrophagemarker CD68 andM2-specificmarker CD163. (D and E)M1- andM2-polarizedMDMs
infected withvA5L-YFP at anMOI of 5 for 24 h were stained for surface CD68 (D) or CD163 (E) and analyzed by FACS. (F) The degrees of VACV binding to and
early infection of MDM subtypes were determined by FACS. MDM subtypes were incubated with vA5L-YFP at anMOI of 5 on ice for 30 min or with VV-EGFP
at an MOI of 5 for 6 h and then subjected to FACS to determine the efficacy of VACV binding and early infection. (G) Apoptosis and necrosis of infected
monocytes and MDMs were detected using intracellular caspase-3 staining and PI staining, respectively, at 6 h, 24 h, and 48 h postinfection. All data are
representative of cells derived from five blood donors. ns, not significant.
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MDMs (data not shown). The increasing presence of multinucle-
ated cells was also evident over the course of infection. Macro-
phages typically fuse together to form multinucleated cells (giant
cells), and this process is associated with granulomas and may
occur in response to the presence of foreign bodies and certain
pathogens. We found that 4.5%  1.6% (n 
 6) of cells were
multinucleated at the start of infection, which increased to
19.4% 5.0% (n
 6) after 24 h of infection (Fig. 2G). Together,
our data indicate that VACV factory formation and VACV-asso-
ciated actin tails occur in infected primary MDMs but not in pri-
mary monocytes. Additionally, VACV dissemination may occur
through routes of cell-to-cell transmission via actin tails, lamelli-
podia, or branching structures.
MDMs mainly produced enveloped forms of VACV. When
we used the virus plaque assay to measure VACV titers in culture
supernatants and cell pellets from infectedM1- andM2-polarized
MDMs, we found that supernatants contained more infectious
virions than did cell lysates (Fig. 3A), with 3-fold and 5-fold higher
numbers of PFU than those in cell lysates of M1 and M2, respec-
tively. Given that VACV infection for 2 days did not cause signif-
icant cell apoptosis and death to release IMV virions into the cul-
ture supernatants, our result suggests that most virions produced
in MDMs are in the form of EEV. The cell-associated virions
titrated by the virus plaque assay could either be IMV within the
cell, CEV attached to the cell surface, EEV bound to the cell sur-
face, or virus particles from the input of the primary infection. The
proportion of intracellular versus extracellular cell-associated vi-
rus was determined by confocal microscopy using vA5L-YFPwith
Ab staining of surface VACV envelope protein A33. By this ap-
proach, intact virus particles inside or outside the cells can be
visualized with vA5L-YFP, while cell surface-attached virions are
seen by A33 staining of vA5L-YFP virions. For the first 3 h of
infection, 5.7% 4.9% of cell-associated virions were CEV/EEV
(Fig. 3B, yellow merged from A33 red stain and vA5L-YFP green
stain, and C), which most likely were left over from the primary
virus input. By 24 h of infection, the total number of virions
greatly increased and the percentage of CEV/EEV rose to 28.9%
16.7% (Fig. 3B and C). By 48 h, the majority of cell-associated
virions were CEV/EEV, at 68.6% 11.0% (Fig. 3B and C). These
data suggest that, by 48 h of infection, the majority of cell-associ-
ated virions measured in Fig. 3A is in the CEV or reattached EEV
form.
To analyze the proportion of enveloped versus mature VACV
forms, virions were collected from cells and supernatants, puri-
fied, combined, and separated by aCsCl density gradient ultracen-
trifugation. The CsCl density gradient is able to separate envel-
oped virions (EV) (including EEV and CEV) that have a lower
buoyant density corresponding to 1.23 to 1.24 g/ml CsCl in a
continuous gradient from single-membrane IMV particles that
have a higher buoyant density of 1.27 to 1.28 g/ml (44). For M2
FIG 2 Virus factories, actin tails, and branching structures formed in VACV-infected macrophages. Primary monocytes (A) andM2-polarized MDMs (B to F)
were infected with vA5L-YFP (green) at an MOI of 5 for various times as indicated and visualized along with F-actin staining with phalloidin (red) and DNA
staining with DAPI (blue). Micrographs exhibited common structures found throughout infection, namely lamellipodia and branching (B, E, and F), virus
factories (C), and actin tails (D). (F) Virus-associated branching structures were also viewed via transillumination. (G) Giant cell formation throughout VACV
infectionwas observed, andmultinucleated cells were counted at various time points. Scale bars represent 10M.All data are representative of cells derived from
five blood donors. *, P 0.05; **, P 0.01.
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cells, analysis of fractions from the gradient revealed that most
virus particles were enriched in the fraction associated with EV
buoyant density (Fig. 3D), with an estimated 3.8 times the number
of VACV particles calculated in the IMV form. This is in contrast
to VACV virions that are produced by the CV-1 cell line (Fig. 3D),
with an estimated 4.1-fold higher number of IMV relative to frac-
tions associated with EV. This result from infected CV-1 cells is
typical of most cell lines infected with VACV WR. Overall, our
results indicate that VACV produced in MDMs is mainly EEV
released into the supernatant, and that by 48 h of infection most
cell-associated VACV is CEV/EEV.
VACV-associated signaling pathways were required for vi-
rus replication inMDMs.VACV is dependent on Akt and Erk1/2
signaling pathways for entry and replication (45–48). Since we
have discovered thatM1 andM2 cells are permissive to VACV, we
sought to analyze the dependence of these two pathways onVACV
replication in MDMs independent of binding and entry. M2-po-
larized cells were infected with VACV at an MOI of 5 for 3 h and
then treated with various concentrations of the Akt inhibitor
LY294002 and the Erk1/2 inhibitor PD98059. LY294002 reduced
the amount of pAkt and PD98059 reduced the amount of pErk1/2
in a dose-dependentmanner (Fig. 4A).We found that both inhib-
itors reduced virus replication in a dose-dependent manner (Fig.
4B), suggesting that Akt and Erk pathways play a critical role in
VACV replication in MDMs, which is in agreement with the re-
sults obtained fromVACV infection in cell lines. Interestingly, the
effects of both GM-CSF andM-CSF onMDMdifferentiation and
maturation rely on activation of the Akt and Erk pathways.
Effects of macrophage activation on VACV replication. In
general, classical (M1) activation of macrophages in response to
FIG 3 MDMs mainly produced enveloped forms of VACV. (A) M1- and M2-polarized MDMs were infected with VACV WR at an MOI of 5. Virions were
extracted from either infected cells or culture supernatant (sup) at 3 h, 24 h, and 48 h postinfection and subjected to virus titration using the virus plaque assay.
(B) M2-polarized cells were infected with vA5L-YFP (green) at an MOI of 5 for various times as indicated and then subjected to surface staining of VACV
envelope protein A33 (red) with confocal microscopy analysis. Scale bars represent 10 M. (C) The number of extracellular (vA5L-YFP plus A33 staining) and
intracellular (vA5L-YFP only) cell-associated virions were counted at different time points as indicated. (D) Purified VACV particles from VACVWR-infected
M2-polarized cells and CV-1 cells were extracted from cell lysates and supernatants and analyzed by separation on a CsCl density gradient. Fractions from the
gradients were tested for absorbance at 260 to estimate the amount of virus particles corresponding to the buoyant densities of mature or enveloped forms of
VACV. All data are representative of cells derived from five blood donors. EV, enveloped virus; IMV, intracellular mature virus.
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IFN- and LPS stimulation exhibits an inflammatory phenotype.
Alternative (M2) activation of macrophages can be induced via a
variety of cytokines and reagents, including LPS, immune com-
plexes, glucocorticoids, IL-1, IL-10, transforming growth factor
beta (TGF-), and Th2 cytokines, such as IL-4 and IL-13. These
cytokines and reagents can produce different cell types with
unique functions. To further probe the unique macrophage-re-
lated pathways related to VACV infection in MDMs, M1 and M2
activations were induced to observe the effects on virus replica-
tion. Activation effects on infection may implicate specific mac-
rophage-associated signaling pathways that are critical for VACV
infection andmay simulate the infection of these cells as they exist
in vivo. M1-polarized cells activated by LPS and IFN- and M2-
polarized cells activated by either IL-4 (M2a), LPS plus IL-1
(M2b), or IL-10 (M2c) for 2 days were analyzed with RT-PCR for
commonM1 andM2 activationmarkers. M1 activation exhibited
higher levels of IL-6 mRNA associated with classical activation,
while M2-activated cells had higher mRNA levels of arginase 1
(Arg-1), CD163, and IL-10 (Fig. 5A) associated with alternative
activation. In addition, LPS-plus-IFN--treated cells expressed
higher levels of theM1 activationmarker CD86 on the cell surface
(Fig. 5B).M1- orM2-polarized cells were infectedwithVACVWR
at an MOI of 5 for 3 h and then subjected to cell activation. Acti-
vation ofM1-polarized cells with LPS plus IFN- had no effect on
VACV replication, as VACV plaque numbers were not affected
(Fig. 5C). Similarly, activation of M2-polarized cells by IL-4 had
no effect on VACV replication, but treatment with LPS plus IL-1
or with IL-10 significantly reduced VACV productivity (Fig. 5C).
At 48 h of infection, activation of M2b and M2c reduced VACV
plaques from 1.22  106  0.13  106 in M2-polarized cells to
0.55 106 0.06 106 and 0.20 106 0.05 106, respectively.
In T cells and macrophages, it has been shown that the down-
stream effects from IL-10 receptor activation largely act through
the Jak/Stat pathway with Stat3 as a prominent transcription fac-
tor. We used cucurbitacin I, a specific inhibitor of Jak2/Stat3, to
probe the effect of Stat3 activation on VACV replication. Com-
pared to untreated M2 cells, M2c cells had significantly higher
levels of pStat Y705 as determined by FACS, indicating IL-10 ac-
tivates Stat3. BothM2-polarized andM2c cells treatedwith cucur-
bitacin I had reduced levels of activated Stat3 (Fig. 5D). When
M2c cells were infected with VACV WR at an MOI of 5 for 3 h,
followed by addition of cucurbitacin I, VACV production in-
creased to the level ofM2 cells without IL-10 stimulation (Fig. 5E).
For example, infected M2 cells treated with IL-10 for 48 h pro-
duced 0.5  106  0.2  106 PFU, while cells treated with IL-10
plus 5 M cucurbitacin I produced 1.4  106  0.1  106 PFU.
Surprisingly, M2-polarized cells even without IL-10 treatment
producedmore VACV in response to the inhibitor treatment (Fig.
5E). After 48 h of incubation, untreated M2-polarized cells pro-
duced 1.3 106 0.1 106 PFU, while cells treated with 5 M
cucurbitacin I produced 1.8 106 0.1 106 total PFU. Overall,
these data demonstrate thatM1 orM2a activation has no effect on
VACV replication, butM2b andM2c activationmarkedly reduces
virus production.WithM2c activation, a Jak2/Stat3 inhibitor res-
cued virus production to levels comparable to those of cells with-
out IL-10 treatment.
DISCUSSION
The primary human cell types, including epithelial cells, keratino-
cytes, and fibroblasts in the airway, skin, and other tissues, have
been considered the main workhorse for orthopoxvirus infection
and replication. In one report, primary human dermal microvas-
cular endothelial cells (HMVEC), fibroblasts, and keratinocytes
were infected in vitrowith VACVWRat anMOI of 10 for 60 h and
produced 197.8, 129.1, and 21.8 PFU/cell, respectively (18). The
result is comparable to our data where, after 48 h of infection,
M1-polarized MDMs produced 15.3 1.2 PFU/cell and M2-po-
larized cells produced 31.7 3.1 PFU/cell when VACV was used
at an MOI of 5 (Fig. 1C), suggesting that macrophages are a sig-
nificant source of viral load in vivo. Previously, the only primary
human leukocyte type known to be permissive to VACV was ac-
tivated T cells (35). Among primary human leukocyte subtypes,
VACV is able to bind to monocytes, activated T cells, B cells, and
neutrophils (35, 49, 50), but it is able to express only viral genes in
monocytes and activated T cells to a significant degree (49, 51, 52).
Primary human monocytes and B cells have been shown to ex-
press little or no VACV late gene A56 (35), suggesting that these
cell types are abortive. We have corroborated this result by show-
ing no virus production in primary human monocytes using the
virus plaque assay. In contrast tomonocytes,MDMs derived from
GM-CSF or M-CSF are permissive to VACV, but MDMs derived
from human AB serum alone are abortive (Fig. 1A and C). In
comparison to human AB serum alone, it is known that GM-CSF
or M-CSF supplementation promotes survival of MDMs (34),
FIG 4 VACV-associated signaling pathways were required for VACV replication in MDMs. M2-polarized MDMs were infected with VACVWR at an MOI of
5 for 3 h. Cells were washed and treated with either 5M, 10M, or 40MLY294002 (Akt inhibitor) or 1M, 10M, or 100MPD98059 (Erk inhibitor). Cell
lysates were collected at 3 h, 24 h, and 48 h postinfection. DMSO, dimethylsulfoxide. (A) Lysates were analyzed by a sandwich ELISA coated with anti-Akt or
anti-Erk1/2 Abs and treated with secondary Abs against pAkt, pErk, or total target proteins. (B) Virions were extracted from cellular lysates at the time points
indicated and titrated by the virus plaque assay. All data are representative of cells derived from five blood donors. *, P 0.05.
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increases cell proliferation (53), increases tumoricidal activity
(21), and alters the expression of certain cell surface markers (53).
VACV-infected GM-CSF-derived MDMs (M1) produce about
half the amount of infectious virions produced byM-CSF-derived
cells (M2) (Fig. 1C). The mechanisms underlying this difference
are not clear, but theymay be related to biological functions ofM1
cells versus M2 cells. M1 cells are well-known proinflammatory
macrophages, whereas M2 cells are anti-inflammatory macro-
phages. M1 cells express proinflammatory cytokines (54, 55) and
are inducible to produce antiviral factors, including IFN regula-
tory factors 4 and 5 (IRF-4 and IRF-5) (56). These proinflamma-
tory cytokines and antiviral factors may contribute to the reduced
VACVproduction in infectedM1macrophages. In fact, IFN treat-
ment can greatly diminish VACV titers in vivo (57), despite the
FIG 5 Effects of macrophage activation on VACV replication. M1-polarized cells were infected with VACVWR at anMOI of 5 for 3 h and then stimulated with
LPS plus IFN-. M2-polarized cells were infected with VACVWR at an MOI of 5 for 3 h and then were stimulated with IL-4 (M2a), LPS plus IL-1 (M2b), or
IL-10 (M2c). (A) After 24 h of stimulation, total RNA was extracted from cells and then subjected to cDNA synthesis and RT-PCR to detect expression of
activation-associated genes of M1 (IL-6) and M2 (Arg-1, CD163, and IL-10). (B) M1 activation marker CD86 on the surface of activated M1 cells was analyzed
using FACS. (C) The virus plaque assay was used to titrate infectious virus copies in the cellular lysates of M1- or M2-polarized cells in the different activation
states. (D)M2-polarized cells were stimulatedwith IL-10with or without cucurbitacin I and then subjected to analysis of Stat3 activation by intracellular staining
with anti-pStat3 Y705 and FACS. (E) The virus plaque assay was used to titrate infectious virus copies in the cell lysates from IL-10 or IL-10-plus-cucurbitacin
I-treated cells after 3 h, 24 h, and 48 h of infection. All data are representative of cells derived from five blood donors. M1act, activatedM1 cells; Cu, cucurbitacin
I. *, P 0.05; **, P 0.01.
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fact that poxviruses have evolved numerous strategies to counter
host antiviral responses (58). Thus, the IFN-related pathwaysmay
also contribute to the reduced viral titer observed from M1 mac-
rophages.
M-CSF binds to cell surface colony-stimulating factor 1 (c-
Fms) to trigger dimerization and subsequent autophosphoryla-
tion of tyrosine residues, which serve as binding sites for SH2
domains of signaling molecules (59). Ultimately, this leads to the
activation of Erk1/2, p38 MAPK, and Akt to promote monocyte
survival and differentiation (60–65). GM-CSF receptor activation
is followed by Jak2 phosphorylation of receptor tyrosines and
eventual activation of Stat5 and the MAPK pathways via Grb2,
Shc, and SHP2 (66). Similarly, VACV is reported to be dependent
on MAPK signaling for replication (45, 46, 47). We observed sig-
nificantly decreased viral production with treatment of Akt and
Erk inhibitors (Fig. 4B), although the off-target effects of each
inhibitor cannot be excluded. Even though the degree of this loss
of virus production may not significant enough to be clinically
relevant, this result demonstrates a similar sensitivity of VACV to
signal transduction pathways previously shown in cell lines.
VACV infection itself induces the activation of the Akt and Erk1/2
pathways in primary human monocytes (67), and viral protein
production is dependent on activation of these pathways (67).
Since monocytes are abortive to VACV infection, it is likely that
the stimulation of these two pathways alone is not sufficient to
induce permissiveness inmonocytic cells. In primary T cells and T
cell lines, tyrosine phosphorylation of CCR5 alone allows cells to
become permissive toVACV replication (68, 69), and such a path-
way may be significant for the induction of permissiveness in
monocytic cells.
In vitro activation ofMDMs in some ways reflects macrophage
activation states in vivo in certain diseases (25, 27). The different
macrophage activation states may alter susceptibility of these cells
to virus infection and replication. For example, M1 and M2a ac-
tivation inhibits HIV-1 replication through different mecha-
nisms, and once activation is resolved,HIV-1 replication increases
(70).We found thatM1 activation resulted in no change to VACV
production (Fig. 5C). This is counterintuitive because of themany
antiviral factors induced with LPS and IFN- stimulation (71),
although VACV has evolved dozens of strategies to evade such
antiviral responses (72). This resultmay reflect howM1-polarized
cells induced by VACV focus inflammation react to VACV infec-
tion in vivo. M2-polarized M-CSF-derived MDMs are considered
a model for normal tissue macrophages (73, 74), as M-CSF is
ubiquitously expressed in the blood and many tissues (75, 76).
Alternative activationwith IL-4 treatment had no detectable effect
on VACV replication (Fig. 5C), which is consistent with similar
transcriptional profiles of M-CSF-treated versus IL-4-treated
MDMs (73). Thus, this result may model how M2-polarized or
M2a tissue macrophages react to primary VACV infection in vivo.
However, alternative activation with IL-10 or with LPS plus IL-1
significantly reduced virus production (Fig. 5C). M2b activation
in macrophages is unique among the routes of alternative activa-
tion, because it induces IL-10 and low levels of IL-12, as well as
high levels of inflammatory cytokines (77). This inflammatory
responsemay induce expression of antiviral factors (such as type I
IFNs) that contribute to the diminished levels of VACV produc-
tion. In different cell types, many of the IL-10 effects are mediated
via the activation of the Jak2/Stat3 pathway, with Stat3 being a
crucial factor for alternative activation in macrophages and im-
mune homeostasis. VACV infection does not block Stat3 activity
but does dephosphorylate Stat1 to reduce the effect of IFN stim-
ulation (78). In general, M1 activation involves Stat1 activation,
whilemuchof the effect ofM2 activation centers on Stat6 (27).We
found that the Jak2/Stat3 inhibitor cucurbitacin I increased
VACV production in both M2-polarized and M2c-activated cells
in a manner correlative to Stat3 activation (Fig. 5D to F).
M1macrophages are critical components of the antitumor im-
mune response.However, tumors and the environmental cues can
polarize M1 toward the M2 phenotype that assists tumor growth
(79). If macrophages are a significant source of viral titer in vivo,
we believe the IL-10/Stat3-mediated reduction of VACV produc-
tion is relevant to potential oncolytic VACV therapies. The effi-
cacy of an oncolytic virus is determined not only by its ability to
specifically target and kill tumor cells but also by its ability to
propagate and spread efficiently among cells within a tumor.
IL-10 produced by T regulatory cells in many types of cancer has
been associated with a reduction of Th1 responses that regulate
IFN- and CD8 cell antitumor immunity (80–82). This role of
IL-10 as an anti-inflammatory agent in tumors is significant for
the use of VACV as an oncolytic agent, as we have found that
VACV replication inMDMs is sensitive to IL-10 stimulation. Our
results suggest that cancer therapies diminishing the effects of
IL-10 are complementary to oncolytic VACV therapy by boosting
the viral titer and dissemination within a tumor. Our finding that
MDMs produced an unusually large amount of EEV is also
uniquely relevant for oncolytic VACV therapy, because the level of
EEV in a tumor was found to be positively correlated with the
effectiveness of treatment (83).
Our study also provides several lines of evidence that primary
macrophages promote VACV dissemination: (i) high EEV pro-
duction, (ii) actin tail-associated CEV, and (iii) VACV-associated
cell branching and linkages. IMV is often considered the most
abundant infectious form of VACV produced in most cell types.
The CEV form of VACV mediates cell-to-cell spreading, and de-
tachment of CEV to become EEV mediates longer-range dissem-
ination (8, 84). We observed that by 48 h of infection with VACV
WR, EEVs were the dominant virus form produced in MDMs
(Fig. 3A andD). This principle is comparable to that for the rabbit
kidney cell line RK-13, which produces significantly more EEV
than other cell lines (85). Additionally, the VACV strain IHD-J
produces high EEV titers in cell lines, especially in RK-13 (85).
Compared to the VACV WR strain, IHD-J produces more EEV
particles because it releases more CEV into the supernatant, while
strains like VACV WR retain CEV on the cell surface (84). Thus,
considering the paradigm in EEV production that exists between
WR and IHD-J cell lines, this anomaly in MDMs will likely be
explained by a host cell-related mechanism like that of RK-13
rather than a characteristic of the virus strain. In cell lines, differ-
ent factors have been associated with EEV production, including
the Abl tyrosine kinases (42, 86) and SH2 domain-containing
phosphoinositide 5-phosphatase 2 (SHIP2) (87), which may be
involved with the high EEV production seen in MDMs.
In conclusion, human primary macrophages are an additional
leukocyte type that is permissive to VACV. After infection, these
cells produce EEV for long-range dissemination and also form
actin tails, cell linkages, lamellipodia, and branching structures
associated with virions, which may contribute to cell-to-cell
spread. Differentmacrophage subtypes and activation states affect
VACV infection and replication. Therefore, macrophages may be
Byrd et al.
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a significant source of viral load in vivo and promote long-range
dissemination.
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